Brief: 2cureX Establishes Collaboration With Scandion Oncology And Erasmus Medical Centre

2cureX AB

16/06/2020 09:36

June 16 (Reuters) - 2cureX AB  2CUREX.ST :
    * 2CUREX AB ESTABLISHES COLLABORATION WITH SCANDION ONCOLOGY
A/S
AND ERASMUS MEDICAL CENTRE, ROTTERDAM, IN DRUG-RESISTANT BREAST
CANCER PATIENTS
    * 2CUREX AB ESTABLISHES COLLABORATION WITH SCANDION ONCOLOGY
A/S
AND ERASMUS MEDICAL CENTRE, ROTTERDAM, IN DRUG-RESISTANT BREAST
CANCER PATIENTS
    * TODAY ANNOUNCES THAT IT TOGETHER WITH SCANDION ONCOLOGY
A/S,
COPENHAGEN AND ERASMUS MEDICAL CENTRE, ROTTERDAM HAS RECEIVED A
GRANT OF 800.000 EUR FROM EUROSTARS
    * GRANT WILL BE USED TO STUDY IF SCANDION ONCOLOGY'S DRUG
CANDIDATE, SCO -101 CAN OVERCOME RESISTANCE TO ANTIESTROGEN
THERAPY IN METASTATIC BREAST CANCER PATIENTS, AND IF 2CUREX'S
INDITREAST TEST CAN STRATIFY SUCH PATIENTS BASED ON SCO-101
SENSITIVITY

Source text for Eikon:  ID:nWkrcdW0VC 
Further company coverage:  2CUREX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))